Laurent Fischer, Adverum CEO (Frazier Healthcare Partners)
April 28, 2021 04:42 PM EDTUpdated 05:04 PM
Cell/Gene Tx

Gene ther­a­py tri­al is de­railed af­ter get­ting hit by the lat­est se­ri­ous ad­verse event in the field — shares crash

John Carroll

Editor & Founder

You can rack up an­oth­er se­ri­ous safe­ty con­cern flagged by a gene ther­a­py de­vel­op­er.

To­day it’s Ad­verum, which is re­port­ing that a pa­tient who re­ceived …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times